WaveMan
WaveMan · Company
NMR · Nomura Holdings Inc
> Search tickers & screens ⌘K
LIVE
← All companies

NMR Nomura (NMR) Insider Trading, Ownership & Congress Trades

Financial Services · Security brokers, dealers & flotation companies · CIK 0001163653
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
236
13F, latest reported quarter

Nomura insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for NOMURA HOLDINGS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Ishizuka Masahiro
Director
BUY
2026-03-27 SECtraded 2026-03-25
238.19
$1.9K
+18.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 70.9% of the 335 shares held after it.
  • 2 other insiders bought within 30 days.
  • 236 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ishizuka Masahiro bought about $1.9K of NMR on Mar 25, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 236 funds added in the latest 13F quarter.
Ogawa Shoji
Director
BUY
2026-03-27 SECtraded 2026-03-25
238.19
$1.9K
+18.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 86.0% of the 276 shares held after it.
  • 2 other insiders bought within 30 days.
  • 236 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ogawa Shoji bought about $1.9K of NMR on Mar 25, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 236 funds added in the latest 13F quarter.
Ozaki Yukiko
See Remarks
BUY
2026-03-26 SECtraded 2026-03-25
7.94
$64
+18.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 12.7% of the 62 shares held after it.
  • 2 other insiders bought within 30 days.
  • 236 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Ozaki Yukiko bought about $64 of NMR on Mar 25, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 236 funds added in the latest 13F quarter.
3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
236 funds bought in last quarter
more than 81% of Financial Services
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.5 days to cover · settled 2026-10-15
below 92% of Financial Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NMR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+29.2%12M
-1%+18%+37%+56%2025-102025-122026-022026-042026-062026-082026-10 2026-03-25 · Ishizuka Masahiro bought $1.9K2026-03-25 · Ogawa Shoji bought $1.9K2026-03-25 · Ozaki Yukiko bought $64
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NMR: institutional holders (13F)

13F holdings, latest reported quarter
LPL Financial LLC
7,332,502 sh
$297.3M
Fisher Asset Management, LLC
13,163,419 sh
$115.6M
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
4,017,655 sh
$110.4M
DONALD SMITH & CO., INC.
12,211,249 sh
$107.2M
MORGAN STANLEY
10,811,519 sh
$94.9M

Congress trades in NMR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NMR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NMR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Nomura VIP Pathfinder Aggressive Series
$4.5M position · as of 2026-06-30
8.8%
Nomura VIP Pathfinder Moderately Aggressive Series
$35.9M position · as of 2026-06-30
8.2%
Nomura VIP Pathfinder Moderately Aggressive - Managed Volatility Series
$3.9M position · as of 2026-06-30
8.1%
Nomura VIP Pathfinder Moderate Series
$27.3M position · as of 2026-06-30
7.8%
Nomura VIP Pathfinder Moderate - Managed Volatility Series
$25.3M position · as of 2026-06-30
7.7%
Nomura VIP Pathfinder Moderately Conservative - Managed Volatility Series
$1.4M position · as of 2026-06-30
7.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 236 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
MSTRCOINMORNUPSTIBKRCACCARESHOODRKTSCHWGSDAVE

NMR financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
4.67x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$13.0T
market value at close 2026-10-26 on 2026-03-31 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-032023-03
Revenue$4.8T$4.7T$4.2T$2.5T
Net income$362.1B$340.7B$165.9B$92.8B
EPS (diluted)n/an/an/an/a
Operating cash flow-$843.0B-$678.6B$132.6B-$694.8B
Cash$4.3T$4.4T$4.2T$3.8T
Long-term debt$15.5T$13.4T$12.5T$10.4T
Buybacks$101.5B$59.0B$61.0B$24.7B
Dividends paid$179.7B$112.5B$60.2B$57.3B
SEC XBRL, fiscal years, as known on 2026-10-28

NMR Stock Sonar score 4/7 axes

Find similar shapesCompare

NMR ranks highest on risk and compliance (95th percentile) and institutional and government (81st), and lowest on financial health (7th), among Financial Services peers.

Financial health
7
Inputs
  • Debt to equity4.67x · 7 pct, sector of 181
  • Cash flow to debtneeds four quarters of operating cash flow
Growth
8
Inputs
  • Revenue growth, YoYno revenue for this year and the year before
  • Backlog growth, YoY-46.7% · 8 pct, universe of 855
Institutional and government
81
Inputs
  • Funds adding, latest quarter236 · 81 pct, sector of 278
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
95
Inputs
  • Short interest, % of float+0.0% · 95 pct, sector of 388
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies